Back to Search
Start Over
The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial.
- Source :
-
European journal of heart failure [Eur J Heart Fail] 2014 Mar; Vol. 16 (3), pp. 334-41. Date of Electronic Publication: 2013 Dec 14. - Publication Year :
- 2014
-
Abstract
- Aim: Acute decompensated heart failure (ADHF) is associated with significant morbidity and mortality but the relationship between LVEF and outcomes is unclear. We explored the association between LVEF and 30 and 180 day mortality in 7007 ADHF patients enrolled in the Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial.<br />Methods and Results: We explored the association between LVEF and 30 and 180 day mortality in 7007 ADHF patients enrolled in the Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF) trial. LVEF was analysed both as a continuous variable and according to three categories: < 40% (LowEF), 40-50% [intermediate EF (IntEF)], and > 50% [preserved ejection fraction (PresEF)]. Of the patients in the trial, 4474 (78.7%) had LowEF, 674 (11.9%) had IntEF, and 539 (9.5%) had PresEF. The unadjusted 30 and 180 day mortality was similar for LowEF (3.7%, 12.3%), IntEF (3.4%, 13.1%), and PresEF (4.3%, 14.1%), respectively (P > 0.05). After multivariable adjustment, the hazard ratio (HR) for 180 day mortality remained similar for the LowEF [HR 0.96, 95% confidence interval (CI) 0.75-1.24; P = 0.77] and IntEF (0.91, 95% CI 0.66-1.3; P = 0.58) compared to PresEF patients. By contrast, when LVEF was evaluated as a continuous measure, it exhibited a U-shaped pattern with mortality. After matching for age and sex, the mortality risk attributed to LVEF was attenuated, as the LVEF increased as a continuous variable over 35%. However, in patients with EF < 35%, the mortality risk continue to increase as the LVEF declined.<br />Conclusions: Among patients with ADHF, the unadjusted mortality rates are similar across LVEF strata. However, after accounting for key patient variables, the mortality risk increases as EF falls below 35%. These data will be useful in planning future studies of ADHF.<br />Clinical Trial Registration: www.clinicaltrials.gov identifier: NCT00475852.<br /> (© 2013 The Authors. European Journal of Heart Failure © 2013 European Society of Cardiology.)
- Subjects :
- Acute Disease
Aged
Aged, 80 and over
Female
Heart Failure drug therapy
Heart Failure physiopathology
Humans
Male
Middle Aged
Natriuretic Agents therapeutic use
Natriuretic Peptide, Brain therapeutic use
Prognosis
Stroke Volume
Survival Rate
Ventricular Dysfunction, Left drug therapy
Ventricular Dysfunction, Left physiopathology
Heart Failure mortality
Ventricular Dysfunction, Left mortality
Subjects
Details
- Language :
- English
- ISSN :
- 1879-0844
- Volume :
- 16
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- European journal of heart failure
- Publication Type :
- Academic Journal
- Accession number :
- 24464687
- Full Text :
- https://doi.org/10.1002/ejhf.19